Adults who use the prescription drug metformin to treat their type 2 diabetes have a lower risk of developing long COVID or dying after a COVID-19 infection than people with diabetes who take other anti-diabetes medications, according to a large study supported by the National Institutes of Health (NIH).
The findings, published in the journal Diabetes Care, were based on health data from millions of U.S. patients and could have broader implications for use of metformin in long COVID prevention generally. The study is part of the NIH-funded Researching COVID to Enhance Recovery (NIH RECOVER) Initiative.
An earlier NIH-supported clinical trial in 2023 showed that treatment with metformin, commonly used to help control blood sugar, reduced the risk of long COVID by as much as 40% in nearly 1,300 U.S. adults with overweight or obesity, most of whom did not have diabetes. To see if the drug had a similar effect in people with diabetes, researchers examined electronic health record data for nearly 38 million Americans from two large U.S. databases.
The researchers compared health records from 75,996 adults taking metformin for their type 2 diabetes to 13,336 records from patients who were not taking metformin but were using other types of diabetes medicines. Researchers were specifically looking at how many patients either died or were diagnosed with long COVID within six months after infection. They found that patients taking metformin had a 13% to 21% lower incidence of long COVID or death than those in the non-metformin group.
Scientists are not clear how metformin may prevent long COVID, but they speculate the possibility of several mechanisms that reduce inflammation, decrease viral levels, and suppress the formation of disease-related proteins.
